Back to search results

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE2

Conditions

Atopic Dermatitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Atd002 52021, Oceanside, California, United States

  • Atd002 52008, Santa Monica, California, United States

  • Atd002 52013, Boca Raton, Florida, United States

  • Atd002 52007, Miami, Florida, United States

  • Atd002 52003, Miami, Florida, United States

  • Atd002 52015, Savannah, Georgia, United States

  • Atd002 52017, Chicago, Illinois, United States

  • Atd002 52018, Wheaton, Illinois, United States

  • Atd002 52012, New Albany, Indiana, United States

  • Atd002 52014, Bowling Green, Kentucky, United States

  • Atd002 52001, Troy, Michigan, United States

  • Atd002 52009, Troy, Michigan, United States

  • Atd002 52010, Omaha, Nebraska, United States

  • Atd002 52022, New York, New York, United States

  • Atd002 52020, The Bronx, New York, United States

  • Atd002 52019, Philadelphia, Pennsylvania, United States

  • Atd002 52005, Dallas, Texas, United States

  • Atd002 52016, Frisco, Texas, United States

  • Atd002 52011, Frisco, Texas, United States

  • Atd002 52004, Sugar Land, Texas, United States

  • Atd002 41004, Lovech, Bulgaria

  • Atd002 41001, Pleven, Bulgaria

  • Atd002 41007, Plovdiv, Bulgaria

  • Atd002 41002, Sevlievo, Bulgaria

  • Atd002 41003, Sofia, Bulgaria

  • Atd002 41005, Sofia, Bulgaria

  • Atd002 41006, Sofia, Bulgaria

  • Atd002 51002, Edmonton, Canada

  • Atd002 51006, Hamilton, Canada

  • Atd002 51007, Toronto, Canada

  • Atd002 51003, Vancouver, Canada

  • Atd002 42002, Náchod, Czechia

  • Atd002 42001, Prague, Czechia

  • Atd002 42003, Prague, Czechia

  • Atd002 42004, Prague, Czechia

  • Atd002 42005, Prague, Czechia

  • Atd002 43001, Bad Bentheim, Germany

  • Atd002 43005, Dresden, Germany

  • Atd002 43002, Frankfurt, Germany

  • Atd002 43004, Leipzig, Germany

  • Atd002 43003, Lübeck, Germany

  • Atd002 43007, Mahlow, Germany

  • Atd002 44003, Budapest, Hungary

  • Atd002 44001, Debrecen, Hungary

  • Atd002 21001, Habikino, Japan

  • Atd002 21002, Nagasaki, Japan

  • Atd002 21007, Nagoya, Japan

  • Atd002 21005, Sakai, Japan

  • Atd002 21008, Sapporo, Japan

  • Atd002 21004, Tachikawa-shi, Japan

  • Atd002 21006, Yokohama, Japan

  • Atd002 45011, Chorzów, Poland

  • Atd002 45001, Katowice, Poland

  • Atd002 45003, Krakow, Poland

  • Atd002 45007, Krakow, Poland

  • Atd002 45010, Krakow, Poland

  • Atd002 45014, Krakow, Poland

  • Atd002 45004, Lodz, Poland

  • Atd002 45013, Lodz, Poland

  • Atd002 45005, Sosnowiec, Poland

  • Atd002 45009, Tarnów, Poland

  • Atd002 45002, Warsaw, Poland

  • Atd002 45006, Warsaw, Poland

  • Atd002 45008, Wroclaw, Poland

  • Atd002 46004, London, United Kingdom

  • Atd002 46007, London, United Kingdom

  • Atd002 46003, Salford, United Kingdom

  • Atd002 46006, Sheffield, United Kingdom

Study leads

  • UCB Cares

    Study Director

    001 844 599 22733

View source on ClinicalTrials.gov(opens in a new tab)